Did you know?
90 percent of cancer-related deaths occur because a tumor migrates around the patient’s body.
A key to unlock metatasis
The LOXL2 enzyme activity has been linked to the metastasis of a variety of different cancers, including breast, esophageal, colon, and squamous cell cancers.
Researchers analysis of breast cancer patients, found poor survival rates and the spread of some cancers was linked to high levels of the LOXL2 enzyme. This enzyme has been linked to the early stages of metastasis of these cancers into the bloodstream.
Around 47,000 new cases of breast cancer are diagnosed in the UK each year and around 12,000 die from the disease.
Recent studies have shown that the lifetime risk of the disease for women is now one in eight.
Experts blamed lifestyle factors, including obesity and drinking alcohol, for fuelling the rise.
Women are also more likely to have children later in life and fewer offspring, which influences the risk.
In the latest study, published in the journal Cancer Research, experts found that LOXL2 promotes the spread of breast cancer through the way it controls two proteins, TIMP1 and MMP9.
In the mice studies, antibodies and chemicals were used to block LOXL2 activity. This prevented breast cancer from metastasizing to other tissues.
These findings are important are an important role in developing a test to try and predict the possible spread of cancer and possible patient outcomes.
Director of Research and Policy at Breast Cancer Campaign, Arlene Wilkie, said, “by using LOXL2 to predict whose cancer will spread and drugs to block the enzyme to stop this from happening, many more lives could be saved.”
This laboratory research shows great promise and we look forward to seeing how it translates into patients.”
Excerpts courtesy of http://yhoo.it/fzS6Lc
Excerpts courtesy of http://bit.ly/hfwDfB